Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06036836 · ClinicalTrials.gov registry record · Phase 2
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT06036836 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 163 participants.
The verdict
NCT06036836, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate pathologic complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with cutaneous squamous cell carcinoma (cSCC) \[Cohort A\] and to evaluate lenvatinib in combination with coformulated favezelimab/pembrolizumab or pembrolizumab with respect to objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator in participants proficient in mismatch repair (pMMR) endometrial cancer (EC) \[Cohort B\].
Interventions
- BIOLOGICAL pembrolizumab
- DRUG lenvatinib
- BIOLOGICAL favezelimab/pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2023-09-29 |
| Est. Completion | 2026-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06036836
The ClinicalTrials.gov registry entry for NCT06036836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pembrolizumab is the first listed.
NCT06036836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06036836 about?
NCT06036836 is a clinical study titled "Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)". The purpose of this study is to evaluate pathologic complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with cutaneous squamous cell carcinoma (cSCC) \[Cohort A\] and to evaluate len...
What is the current status of trial NCT06036836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2023-09-29. Estimated completion is 2026-03-12.
What interventions are being tested in trial NCT06036836?
The interventions under investigation include: pembrolizumab (BIOLOGICAL), lenvatinib (DRUG), favezelimab/pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06036836?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.